Disease Overview：Mitral regurgitation（MR）
Mitral regurgitation, also known as mitral insufficiency or mitral valve incompetence, is a common valvular heart disease characterized by improper closure of the mitral valve during ventricular systole, resulting in retrograde blood flow from the left ventricle into the left atrium. This hemodynamic abnormality may arise from structural defects—such as leaflet prolapse, chordal rupture, or annular dilation—or functional causes linked to left ventricular remodeling, often secondary to ischemic cardiomyopathy or dilated cardiomyopathy. Clinical presentation ranges from asymptomatic murmurs detected on routine auscultation to progressive dyspnea, fatigue, orthopnea, and, in advanced stages, pulmonary congestion or right-heart failure. Diagnosis relies on transthoracic echocardiography (TTE), supplemented by transesophageal echocardiography (TEE), cardiac MRI, or invasive hemodynamic assessment when indicated. Management spans medical optimization (e.g., diuretics, beta-blockers, ACE inhibitors) to definitive intervention—including surgical mitral valve repair or replacement (via sternotomy or minimally invasive approaches) and transcatheter edge-to-edge repair (e.g., TEER with the MitraClip system)—guided by symptom severity, ventricular function, and anatomical suitability.
China offers compelling advantages for international patients seeking high-quality, cost-conscious care for mitral regurgitation. Leading cardiovascular centers—such as Fu Wai Hospital (National Center for Cardiovascular Diseases), Shanghai Ruijin Hospital, and Beijing Anzhen Hospital—boast internationally trained cardiac surgeons and interventional cardiologists with extensive experience in complex mitral valve repair, robotic-assisted surgery, and TEER procedures. These institutions utilize state-of-the-art imaging (3D TEE, real-time fusion imaging), next-generation bioprosthetic valves, and AI-enhanced procedural planning tools. Clinical outcomes align with global benchmarks: >90% 5-year survival post-repair in eligible patients, and >85% procedural success rates for TEER in high-volume centers. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical rigor—making advanced interventions significantly more accessible. As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital credentials, coordinating pre-arrival diagnostics, arranging appointments with top-tier specialists, providing transparent, all-inclusive pricing (covering surgery, imaging, hospital stay, and follow-up), and offering end-to-end support—from visa assistance and airport transfers to multilingual nursing coordination and postoperative rehabilitation guidance.
Mitral regurgitation: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Mitral Regurgitation (Cardiovascular Department)
I. Non-Surgical / Conservative Management
*Indicated for asymptomatic mild-to-moderate MR, compensated LV function, or high surgical risk.*
- •Pharmacotherapy (3–6 months trial)
- Beta-blockers (e.g., bisoprolol): $8–$22/month - Diuretics (e.g., furosemide): $4–$15/month
- •Monitoring & Diagnostic Fees (per 6-month cycle)
- NT-proBNP assay: $25–$40 - 12-lead ECG + Holter monitoring: $35–$65 - Serum creatinine, electrolytes, LFTs: $20–$35 *Total annual conservative care (meds + monitoring): $320–$780*
II. Surgical & Interventional Options
*Eligibility: Symptomatic severe MR (EROA ≥40 mm², RVol ≥60 mL), LV EF ≤60%, or progressive LV dilation (LVEDD ≥60 mm).*
- •Mitral Valve Repair (Gold Standard)
- Procedure (on-pump, robotic-assisted or sternotomy): $8,900–$14,200 - ICU stay (3–5 days): $1,800–$2,700 - Hospitalization (10–14 days total): $2,200–$3,400 *Total range: $14,050–$22,000*
- •Transcatheter Edge-to-Edge Repair (TEER; e.g., MitraClip)
- Procedure (including device + fluoroscopy suite): $18,500–$24,800 - ICU (1–2 days) + ward stay (5–7 days): $1,450–$2,100 *Total range: $21,270–$28,850*
- •Mitral Valve Replacement (MVR)
- Bioprosthetic valve: $12,400–$17,900 *(Includes pre-op, surgery, ICU, and 12-day hospitalization)*
III. Special/Complex Scenarios
- •MR with Severe Pulmonary Hypertension (mPAP >55 mmHg): Requires right heart catheterization ($850–$1,200) + targeted PAH therapy ($1,100–$2,300/month) prior to valve intervention.
- •Concomitant Atrial Fibrillation & Stroke Risk: Left atrial appendage occlusion (LAAO) added to TEER/MVR (+$3,800–$5,200).
- •Reoperative MR (prior valve surgery): 20–30% higher procedural cost due to adhesions and complexity (+15–25% across all components).
IV. Quick Selection Guide
- •<65 years, no comorbidities, severe primary MR: Surgical repair — optimal durability, lowest long-term cost.
- •≥75 years, frailty/COPD/diabetes, severe MR: TEER — avoids sternotomy, faster recovery, lower 30-day mortality.
- •Budget-constrained (<$10,000 USD): Conservative management + strict serial monitoring, only if asymptomatic and stable.
- •Secondary MR with LVEF <30%: GDMT optimization first (6 months), then reassess — valve intervention rarely beneficial without myocardial recovery.
- •Acute severe MR (e.g., chordal rupture): Urgent surgical repair — costs escalate 18–22% if delayed beyond 48 hours.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Mitral regurgitation Medical Vacation Packages
Curated transparent all-inclusive packages combining Mitral regurgitation treatment with China top medical destinations:
